Congratulations! Beijing Leadingpharm, a Subsidiary of Talong Pharmaceutical, Assists Weixian Pharmaceutical in Securing National Drug Registration Certificate for Sodium Valproate Oral Solution

ZHENGZHOU, China — Zhengzhou Weixian Pharmaceutical Technology has secured approval from China's National Medical Products Administration for its sodium valproate oral solution, a widely prescribed anti-epileptic medication, marking a significant milestone in the company's push into the central nervous system therapeutics market.

The drug, formulated at a specification of 300ml:12g, was approved as a Category 4 chemical generic and has passed China's consistency evaluation for quality and efficacy — a regulatory benchmark that signals the product is interchangeable with its branded counterpart. The approval was announced by Henan Taloph Pharmaceutical Stock Co., Ltd., whose subsidiary Beijing Leadingpharm Medical Technology Co., Ltd. supported the development and regulatory filing.

Sodium valproate is considered a first-line, broad-spectrum treatment for epilepsy, used to manage generalized, partial, and other seizure types. The oral solution formulation offers advantages over traditional tablet forms: a milder taste, more precise dosing, and easier administration — features that make it particularly suitable for children, elderly patients, and those with swallowing difficulties. These attributes are expected to improve long-term medication adherence among chronic epilepsy patients.

China's epilepsy treatment market has long been dominated by older formulations. The entry of a domestically produced oral solution provides patients with a quality alternative to imported products, part of a broader government push to strengthen local pharmaceutical manufacturing and reduce dependence on foreign drug supplies.

For Weixian Pharmaceutical, a Zhengzhou-based platform company focused on drug registration and commercialization, the approval expands its portfolio in the psychiatric and neurological disease segment. The company operates by holding drug registration certificates and partnering with manufacturers to bring products to market — a model that has gained traction in China's evolving pharmaceutical landscape.

Beijing Leadingpharm, the Taloph Pharmaceutical unit that facilitated the development, has positioned itself as a contract research and regulatory services provider, helping partners navigate China's increasingly rigorous drug approval process. The collaboration underscores a trend in which specialized service companies are playing a growing role in bringing generic medicines to market.

Weixian said it plans to accelerate production launch and commercial promotion of the sodium valproate oral solution, as it seeks to capitalize on what it described as clear clinical demand and substantial market potential for the product.

Readers are advised to consult the drug's prescribing information or seek guidance from a physician or pharmacist before use. This article does not constitute medical advice.